SLENYTO® Melatonin Tablets Approved in Canada for Pediatric Insomnia

What's Happening? SLENYTO®, an extended-release melatonin tablet, is now available in Canada as a prescription treatment for insomnia in children and adolescents with autism spectrum disorder (ASD) and Smith-Magenis syndrome (SMS). Developed by Neurim Pharmaceuticals, SLENYTO® is designed to mimic n

Healthy Living

SEE ALL

Rapid Read

Home Gardens Associated with Lower Type 2 Diabetes Risk, Study Finds

Rapid Read

C-Section Births Linked to Changes in Babies' Genes and Gut Microbiota

Rapid Read

South Florida Family Launches Lifesaving Mission After Tragedy

What is the story about?

What's Happening?

SLENYTO®, an extended-release melatonin tablet, is now available in Canada as a prescription treatment for insomnia in children and adolescents with autism spectrum disorder (ASD) and Smith-Magenis syndrome (SMS). Developed by Neurim Pharmaceuticals,

SLENYTO® is designed to mimic natural melatonin secretion and has been clinically evaluated for safety and efficacy in pediatric patients. The approval by Health Canada addresses a significant unmet need for children with these conditions, who often experience disrupted sleep due to altered melatonin secretion.

Why It's Important?

The availability of SLENYTO® in Canada represents a significant advancement in the treatment of sleep disorders in children with ASD and SMS. These conditions are characterized by disrupted circadian rhythms, leading to sleep disturbances that can impact overall health and quality of life. By providing a targeted treatment option, SLENYTO® offers hope for improved sleep and, consequently, better daytime functioning and quality of life for affected children and their families. This development highlights the importance of addressing sleep disorders in pediatric populations and the potential benefits of tailored pharmacological interventions.